Physician profile
Arthur K Mark
NPI 1629037254
$17,598.72
in general payments reported to CMS, 2019-2025
27 companies · $4,163 in 2025
The $4,163 reported for 2025 was more than what 80% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,365 · 2020: $458 · 2021: $422 · 2022: $1,806 · 2023: $693 · 2024: $3,692 · 2025: $4,163.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $4,720 · Food and Beverage: $3,827.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $4,720.12 |
| Food and Beverage | $3,827.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zimmer Biomet Holdings, INC. | $7,412.84 | 2019-2025 | Persona, Mymobility Platform, Rosa |
| Encore Medical, LP | $5,766.84 | 2019 | |
| Stryker Corporation | $1,317.93 | 2019-2025 | Pangea, Gamma, Mako |
| Medical Device Business Services, INC. | $1,156.37 | 2022 | |
| Depuy Synthes Sales INC. | $379.47 | 2019-2025 | Lcp, Monovisc, Orthovisc |
| Davol INC. | $308.14 | 2023-2025 | Arista, Channel Drain |
| Smith+Nephew, INC. | $274.56 | 2025 | Real Intelligence, Redapt, Journey II |
| Intellijoint Surgical INC. | $174.78 | 2022 | |
| Acera Surgical, INC. | $171.21 | 2024-2025 | Restrata Wound Matrix |
| Orthalign INC | $114.48 | 2025 | Orthalign Plus |
| W. L. Gore & Associates, INC. | $94.97 | 2022 | |
| Nevro Corp. | $63.75 | 2019-2023 | Senza |
| Ferring Pharmaceuticals INC. | $48.65 | 2023-2024 | Euflexxa |
| Acumed LLC | $37.18 | 2019 | |
| Biocomposites INC | $33.18 | 2019-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heraeus Medical, LLC. | $32.01 | 2024 | |
| Pacira Pharmaceuticals Incorporated | $30.32 | 2019-2023 | Exparel, Iovera, Zilretta |
| Pacira Therapeutics, INC. | $28.98 | 2020-2021 | |
| Collegium Pharmaceutical, INC. | $27.16 | 2019 | |
| Si-Bone, INC. | $27.07 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $16.88 | 2023 | Seglentis |
| Vertex Pharmaceuticals Incorporated | $15.35 | 2025 | |
| Janssen Pharmaceuticals, INC | $14.22 | 2020 | |
| Biodelivery Sciences International, INC. | $13.64 | 2020 | |
| Scilex Pharmaceuticals INC. | $13.64 | 2019 | |
| Heron Therapeutics, INC. | $12.92 | 2022 | |
| Ethicon US, LLC | $12.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arthur Mark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.